Ahmed AbdElRazik Souka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ahmed AbdElRazik Souka has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Mohammed Ashraf
Beetham Eye Institute, Joslin Diabetes Center, Boston, MA, USA
5 shared publications Ahmad M Mansour
Department of Ophthalmology, American University of Beirut, Beirut, Lebanon
3 shared publications- Abdulrazzak Charbaji
Department of Statistics and Research Methodology, Lebanese American University, Beirut, Lebanon
2 shared publications Jay Chhablani
Smt. Kanuri Santhamma Centre for Vitreoretinal Diseases, LV Prasad Eye Institute, Hyderabad, Andhra Pradesh, India
2 shared publicationsAhmed M. Bedda
Ophthalmology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
1 shared publication- Alaa Atef Ghaith
Alexandria Main University Hospital, Alexandria, Egypt
1 shared publication
Latest Publications
- Open Access
- 1 April 2023
- Published by Egyptian Knowledge Bank in ALEXMED ePosters
- Vol. 5 (2) , 2-3
EVALUATION OF CORNEAL ENDOTHELIAL CELL CHANGES AFTER VITREORETINAL SURGERY USING DIFFERENT ENDOTAMPONADES
A pre-operative clinical estimate of EC using specular microscopy can provide data regarding ECD and morphology, thus facilitating assessment of the functional reserve of the endothelium in individual patients. This analysis provides a measure of the general health of the corneal endothelium, which is important before any intraocular surgery and provide a baseline to predict post-operative outcomes of corneal state that influence patients’ visual outcomes.As an intraocular surgery, vitreoretinal surgery is associated with EC changes. During surgery, factors as intraocular irrigation solution and operation time may affect the corneal endothelium. Also, furthermore damage may be related to the used tamponade.AIM OF THE WORK:The aim of this study was to evaluate the corneal endothelial cell changes after pars plana vitrectomy operations and to compare the results using different types of tamponades (silicon oil and SF6 gas).SUBJECTS AND METHODS:This prospective study consisted of 50 eyes of patients undergoing pars plana vitrectomy surgery. The patients were assigned into two groups according to the retinal tamponade used:Group I were silicon oil filled, and Group II were SF6 gas filled.Central corneal endothelial cell density (ECD), central corneal thickness (CCT), mean cell density (MCD) and mean cell area (MCA), and coefficient of variation (polymegathism) and cell shape (polymorphism) were measured using a non contact specular microscope, preoperative, one month and three month postoperatively.
- 1 April 2023
- Published by Egyptian Knowledge Bank in ALEXMED ePosters
- Vol. 5 (2) , 2-3
Open AccessEVALUATION OF CORNEAL ENDOTHELIAL CELL CHANGES AFTER VITREORETINAL SURGERY USING DIFFERENT ENDOTAMPONADES
A pre-operative clinical estimate of EC using specular microscopy can provide data regarding ECD and morphology, thus facilitating assessment of the functional reserve of the endothelium in individual patients. This analysis provides a measure of the general health of the corneal endothelium, which is important before any intraocular surgery and provide a baseline to predict post-operative outcomes of corneal state that influence patients’ visual outcomes.As an intraocular surgery, vitreoretinal surgery is associated with EC changes. During surgery, factors as intraocular irrigation solution and operation time may affect the corneal endothelium. Also, furthermore damage may be related to the used tamponade.AIM OF THE WORK:The aim of this study was to evaluate the corneal endothelial cell changes after pars plana vitrectomy operations and to compare the results using different types of tamponades (silicon oil and SF6 gas).SUBJECTS AND METHODS:This prospective study consisted of 50 eyes of patients undergoing pars plana vitrectomy surgery. The patients were assigned into two groups according to the retinal tamponade used:Group I were silicon oil filled, and Group II were SF6 gas filled.Central corneal endothelial cell density (ECD), central corneal thickness (CCT), mean cell density (MCD) and mean cell area (MCA), and coefficient of variation (polymegathism) and cell shape (polymorphism) were measured using a non contact specular microscope, preoperative, one month and three month postoperatively.
- Open Access
- 13 January 2021
- Published by Wiley in Journal of Ophthalmology
- Vol. 2021 (1)
Pars Plana Vitrectomy versus Intravitreal Injection of Ranibizumab in the Treatment of Diabetic Macular Edema Associated with Vitreomacular Interface Abnormalities
Purpose . To compare the efficacy of pars plana vitrectomy (PPV) versus intravitreal injection (IVI) of ranibizumab (RBZ) in the treatment of diabetic macular edema (DME) associated with vitreomacular interface abnormalities (VMIA). Methods . The records of patients presenting with DME and VMIA throughout 2016 to 2018 were retrospectively analyzed. The patients were divided into 2 groups: group I received IVIs of RBZ and group II underwent PPV with internal limiting membrane peeling. The main outcome measures were the change in the LogMAR corrected distance visual acuity (CDVA) and central subfield thickness (CSFT) on optical coherence tomography over 6 months. Results . At 6 months, mean CDVA improved by 0.22 ± 0.21 in group I patients ( p < 0.001), while in group II, it improved only by 0.09 ± 0.22 ( p < 0.115). Fifty‐five percent of group I and 60% of group II patients had stable CDVA (within 2 lines from baseline) at 6 months. Significant improvement in vision (gain of 2 or more lines) was seen in 45% and 30%, respectively. Worsening of vision (loss of 2 or more lines) was seen only in 2 patients in group II, but none in group I. The mean CSFT improved significantly in both groups (by 162 µ and 216 µ , respectively; p < 0.001). The mean CSFT at 6 months was similar in both groups (354 µ and 311 µ , respectively; p = 0.172). Conclusions . Both treatments resulted in anatomical improvement of DME with concurrent VMIA. Visual improvement was more pronounced in the IVI group, although this may have been affected by other confounding factors.
- 13 January 2021
- Published by Wiley in Journal of Ophthalmology
- Vol. 2021 (1)
Open AccessPars Plana Vitrectomy versus Intravitreal Injection of Ranibizumab in the Treatment of Diabetic Macular Edema Associated with Vitreomacular Interface Abnormalities
Purpose . To compare the efficacy of pars plana vitrectomy (PPV) versus intravitreal injection (IVI) of ranibizumab (RBZ) in the treatment of diabetic macular edema (DME) associated with vitreomacular interface abnormalities (VMIA). Methods . The records of patients presenting with DME and VMIA throughout 2016 to 2018 were retrospectively analyzed. The patients were divided into 2 groups: group I received IVIs of RBZ and group II underwent PPV with internal limiting membrane peeling. The main outcome measures were the change in the LogMAR corrected distance visual acuity (CDVA) and central subfield thickness (CSFT) on optical coherence tomography over 6 months. Results . At 6 months, mean CDVA improved by 0.22 ± 0.21 in group I patients ( p < 0.001), while in group II, it improved only by 0.09 ± 0.22 ( p < 0.115). Fifty‐five percent of group I and 60% of group II patients had stable CDVA (within 2 lines from baseline) at 6 months. Significant improvement in vision (gain of 2 or more lines) was seen in 45% and 30%, respectively. Worsening of vision (loss of 2 or more lines) was seen only in 2 patients in group II, but none in group I. The mean CSFT improved significantly in both groups (by 162 µ and 216 µ , respectively; p < 0.001). The mean CSFT at 6 months was similar in both groups (354 µ and 311 µ , respectively; p = 0.172). Conclusions . Both treatments resulted in anatomical improvement of DME with concurrent VMIA. Visual improvement was more pronounced in the IVI group, although this may have been affected by other confounding factors.
- 28 February 2020
- Published by BMJ in British Journal of Ophthalmology
- Vol. 104 (12) , 1762-1767
Disparity of microaneurysm count between ultrawide field colour imaging and ultrawide field fluorescein angiography in eyes with diabetic retinopathy
Aims To compare microaneurysm (MA) counts using ultrawide field colour images (UWF-CI) and ultrawide field fluorescein angiography (UWF-FA). Methods Retrospective study including patients with type 1 or 2 diabetes mellitus receiving UWF-FA and UWF-CI within 2 weeks. MAs were manually counted in individual Early Treatment Diabetic Retinopathy Study (ETDRS) and extended UWF zones. Fields with MAs ≥20 determined diabetic retinopathy (DR) severity (0 fields=mild, 1–3=moderate, ≥4=severe). UWF-FA and UWF-CI agreement was determined and UWF-CI DR severity sensitivity analysis adjusting for UWF-FA MA counts performed. Results In 193 patients (288 eyes), 2.4% had no DR, 29.9% mild non-proliferative DR (NPDR), 32.6% moderate (NPDR), 22.9% severe NPDR and 12.2% proliferative DR. UWF-FA MA counts were 3.5-fold higher (pConclusions UWF-FA detects threefold to fivefold more MAs than UWF-CI and identifies 1.6–3.5-fold more fields affecting DR severity. Differences exist at all DR severity levels, thus limiting direct comparison between the modalities. However, correcting UWF-FA MA counts substantially improves DR severity agreement between the modalities. Trial registration number NCT03531294.
- 28 February 2020
- Published by BMJ in British Journal of Ophthalmology
- Vol. 104 (12) , 1762-1767
Disparity of microaneurysm count between ultrawide field colour imaging and ultrawide field fluorescein angiography in eyes with diabetic retinopathy
Aims To compare microaneurysm (MA) counts using ultrawide field colour images (UWF-CI) and ultrawide field fluorescein angiography (UWF-FA). Methods Retrospective study including patients with type 1 or 2 diabetes mellitus receiving UWF-FA and UWF-CI within 2 weeks. MAs were manually counted in individual Early Treatment Diabetic Retinopathy Study (ETDRS) and extended UWF zones. Fields with MAs ≥20 determined diabetic retinopathy (DR) severity (0 fields=mild, 1–3=moderate, ≥4=severe). UWF-FA and UWF-CI agreement was determined and UWF-CI DR severity sensitivity analysis adjusting for UWF-FA MA counts performed. Results In 193 patients (288 eyes), 2.4% had no DR, 29.9% mild non-proliferative DR (NPDR), 32.6% moderate (NPDR), 22.9% severe NPDR and 12.2% proliferative DR. UWF-FA MA counts were 3.5-fold higher (pConclusions UWF-FA detects threefold to fivefold more MAs than UWF-CI and identifies 1.6–3.5-fold more fields affecting DR severity. Differences exist at all DR severity levels, thus limiting direct comparison between the modalities. However, correcting UWF-FA MA counts substantially improves DR severity agreement between the modalities. Trial registration number NCT03531294.
- 11 August 2018
- Published by BMJ in British Journal of Ophthalmology
- Vol. 103 (6) , 805-810
Safety of 5914 intravitreal ziv-aflibercept injections
Purpose To analyse the pooled safety data of intravitreal ziv-aflibercept (IVZ) therapy for various retinal conditions. Methods This was a retrospective, observational study which included patients from 14 participating centres who received IVZ. The medical records of patients who received IVZ from March 2015 through October 2017 were evaluated. Patient demographics and ocular details were compiled. Ocular and systemic adverse events that occurred within 1 month of IVZ injections were recorded and defined as either procedure-related or drug-related. Results A total of 1704 eyes of 1562 patients received 5914 IVZ injections (mean±SD: 3.73±3.94) during a period of 2.5 years. The age of patients was 60.6±12.8 years (mean±SD) and included diverse chorioretinal pathologies. Both ocular (one case of endophthalmitis, three cases of intraocular inflammation, and one case each of conjunctival thinning/necrosis and scleral nodule) and systemic adverse events (two cases of myocardial infarction, one case of stroke and two deaths) were infrequent. Conclusion This constitutes the largest pooled safety report on IVZ use and includes patients from 14 centres distributed across the globe. It shows that IVZ has an acceptable ocular and systemic safety profile with incidences of adverse events similar to those of other vascular endothelial growth factor inhibitory drugs. The analysis supports the continued use of IVZ in various retinal disorders.
- 11 August 2018
- Published by BMJ in British Journal of Ophthalmology
- Vol. 103 (6) , 805-810
Safety of 5914 intravitreal ziv-aflibercept injections
Purpose To analyse the pooled safety data of intravitreal ziv-aflibercept (IVZ) therapy for various retinal conditions. Methods This was a retrospective, observational study which included patients from 14 participating centres who received IVZ. The medical records of patients who received IVZ from March 2015 through October 2017 were evaluated. Patient demographics and ocular details were compiled. Ocular and systemic adverse events that occurred within 1 month of IVZ injections were recorded and defined as either procedure-related or drug-related. Results A total of 1704 eyes of 1562 patients received 5914 IVZ injections (mean±SD: 3.73±3.94) during a period of 2.5 years. The age of patients was 60.6±12.8 years (mean±SD) and included diverse chorioretinal pathologies. Both ocular (one case of endophthalmitis, three cases of intraocular inflammation, and one case each of conjunctival thinning/necrosis and scleral nodule) and systemic adverse events (two cases of myocardial infarction, one case of stroke and two deaths) were infrequent. Conclusion This constitutes the largest pooled safety report on IVZ use and includes patients from 14 centres distributed across the globe. It shows that IVZ has an acceptable ocular and systemic safety profile with incidences of adverse events similar to those of other vascular endothelial growth factor inhibitory drugs. The analysis supports the continued use of IVZ in various retinal disorders.
- 9 January 2018
- Published by BMJ in British Journal of Ophthalmology
- Vol. 102 (10) , 1387-1390
Two-year outcomes of intravitreal ziv-aflibercept
Aim To assess the two-year outcome of intravitreal ziv-aflibercept (IVZ) in eyes with macular diseases. Methods Consecutive subjects with various macular diseases that received six or more of 0.05 mL IVZ (1.25 mg) injections with at least 1 year follow-up were included. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution) and central macular thickness (CMT) on spectral domain optical coherence tomography. Paired comparison was done using Wilcoxon signed-rank test calculator. Results 107 eyes of 91 subjects received IVZ and were followed with mean±SD follow-up interval of 1.48±0.44 months following treat and extend or pro-re-nata protocol. The distribution included neovascular macular degeneration (42 eyes), diabetic macular oedema (32 eyes) and macular oedema secondary to retinal vein occlusion (11 eyes). Fifty eyes were naive, while 57 eyes were previously treated. Combining all disease categories, CMT decreased significantly by 133.0±153.0 µm at the 24-month follow-up (PConclusions IVZ appears safe and efficacious in the therapy of macular diseases through 2 years.
- 9 January 2018
- Published by BMJ in British Journal of Ophthalmology
- Vol. 102 (10) , 1387-1390
Two-year outcomes of intravitreal ziv-aflibercept
Aim To assess the two-year outcome of intravitreal ziv-aflibercept (IVZ) in eyes with macular diseases. Methods Consecutive subjects with various macular diseases that received six or more of 0.05 mL IVZ (1.25 mg) injections with at least 1 year follow-up were included. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution) and central macular thickness (CMT) on spectral domain optical coherence tomography. Paired comparison was done using Wilcoxon signed-rank test calculator. Results 107 eyes of 91 subjects received IVZ and were followed with mean±SD follow-up interval of 1.48±0.44 months following treat and extend or pro-re-nata protocol. The distribution included neovascular macular degeneration (42 eyes), diabetic macular oedema (32 eyes) and macular oedema secondary to retinal vein occlusion (11 eyes). Fifty eyes were naive, while 57 eyes were previously treated. Combining all disease categories, CMT decreased significantly by 133.0±153.0 µm at the 24-month follow-up (PConclusions IVZ appears safe and efficacious in the therapy of macular diseases through 2 years.
- 7 March 2017
- Published by BMJ in British Journal of Ophthalmology
- Vol. 101 (10) , 1374-1376
Long-term safety and efficacy of ziv-aflibercept in retinal diseases
Aims To investigate the long-term safety of intravitreal ziv-aflibercept in eyes receiving six or more intravitreal injections of ziv-aflibercept, an off-label substitute to the approved aflibercept. Methods Consecutive patients with retinal disease receiving six or more of intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections were followed monthly in three centres. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution (logMar)) and central macular thickness (CMT) on spectral domain optical coherence tomography and monitoring for ocular inflammation, progression of lens opacities and intraocular pressure rise. Paired comparison was done using Wilcoxon signed-rank test calculator. Results Sixty-five eyes of 60 consecutive patients received a mean of 8.4 (6–17) intravitreal injections with a baseline mean logMAR BCVA of 0.98±0.56 and CMT 432.7±163.0 μm and followed for a mean of 9.2 months (range 6–18 months). After the sixth injection, mean BCVA improved to 0.57±0.36 (p=0.001) and CMT decreased to 274.8±117.8 μm (p=0.0001). At the 9-month follow-up, mean BCVA improved to 0.62±0.37 (p=0.0004) and mean CMT decreased to 292.0±160.9 μm (pConclusions Repeated intravitreal injections of ziv-aflibercept appear tolerable, safe and efficacious in the therapy of retinal disease.
- 7 March 2017
- Published by BMJ in British Journal of Ophthalmology
- Vol. 101 (10) , 1374-1376
Long-term safety and efficacy of ziv-aflibercept in retinal diseases
Aims To investigate the long-term safety of intravitreal ziv-aflibercept in eyes receiving six or more intravitreal injections of ziv-aflibercept, an off-label substitute to the approved aflibercept. Methods Consecutive patients with retinal disease receiving six or more of intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections were followed monthly in three centres. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution (logMar)) and central macular thickness (CMT) on spectral domain optical coherence tomography and monitoring for ocular inflammation, progression of lens opacities and intraocular pressure rise. Paired comparison was done using Wilcoxon signed-rank test calculator. Results Sixty-five eyes of 60 consecutive patients received a mean of 8.4 (6–17) intravitreal injections with a baseline mean logMAR BCVA of 0.98±0.56 and CMT 432.7±163.0 μm and followed for a mean of 9.2 months (range 6–18 months). After the sixth injection, mean BCVA improved to 0.57±0.36 (p=0.001) and CMT decreased to 274.8±117.8 μm (p=0.0001). At the 9-month follow-up, mean BCVA improved to 0.62±0.37 (p=0.0004) and mean CMT decreased to 292.0±160.9 μm (pConclusions Repeated intravitreal injections of ziv-aflibercept appear tolerable, safe and efficacious in the therapy of retinal disease.
- 26 May 2016
- Published by BMJ in British Journal of Ophthalmology
- Vol. 100 (12) , 1596-1604
Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature
Diabetic macular oedema affects visual acuity to a varying degree. The current treatment of choice is intravitreal anti-vascular endothelial growth factor (VEGF) that has proven both its anatomical and visual efficacy in several large randomised clinical trials (RCTs). Although most patients respond well to anti-VEGF agents, some, however, show a moderate or even poor response. There is no clear consensus as to how to manage these patients, or define them. In addition, identifying early in the course of treatment which patients will respond and which patients will not is paramount to any personalised treatment regimen. Most large RCTs such as RESTORE and Protocol I have attempted post hoc analyses to identify demographic, clinical, optical coherence tomography (OCT) and fluorescein angiography findings that might predict patient response. Although some factors were found to be predictive, the lack of uniformity between the different RCTs means that no consensus exists as to which of these factors can be reliably used. This review looks at the large diabetic macular oedema RCTs such as RESTORE, Protocol I, READ-2 and BOLT in an attempt to identify common prognostic indicators between the various studies. We also attempted to look at several other OCT parameters such as the inner segment-outer segment (IS-OS) layer, the external limiting membrane layer, and choroidal thickness to help determine whether they can truly predict visual outcomes in patients being treated with anti-VEGF therapy. Finally, we provide a simplified summary about which factors might be relevant in clinical practice to help guide physicians in treatment decisions.
- 26 May 2016
- Published by BMJ in British Journal of Ophthalmology
- Vol. 100 (12) , 1596-1604
Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature
Diabetic macular oedema affects visual acuity to a varying degree. The current treatment of choice is intravitreal anti-vascular endothelial growth factor (VEGF) that has proven both its anatomical and visual efficacy in several large randomised clinical trials (RCTs). Although most patients respond well to anti-VEGF agents, some, however, show a moderate or even poor response. There is no clear consensus as to how to manage these patients, or define them. In addition, identifying early in the course of treatment which patients will respond and which patients will not is paramount to any personalised treatment regimen. Most large RCTs such as RESTORE and Protocol I have attempted post hoc analyses to identify demographic, clinical, optical coherence tomography (OCT) and fluorescein angiography findings that might predict patient response. Although some factors were found to be predictive, the lack of uniformity between the different RCTs means that no consensus exists as to which of these factors can be reliably used. This review looks at the large diabetic macular oedema RCTs such as RESTORE, Protocol I, READ-2 and BOLT in an attempt to identify common prognostic indicators between the various studies. We also attempted to look at several other OCT parameters such as the inner segment-outer segment (IS-OS) layer, the external limiting membrane layer, and choroidal thickness to help determine whether they can truly predict visual outcomes in patients being treated with anti-VEGF therapy. Finally, we provide a simplified summary about which factors might be relevant in clinical practice to help guide physicians in treatment decisions.
- 1 June 2015
- Published by Elsevier in Journal Français d'Ophtalmologie
- Vol. 38 (6) , 550-558
Socioeconomic and psychological impact of treatment for unilateral intraocular retinoblastoma
- 1 June 2015
- Published by Elsevier in Journal Français d'Ophtalmologie
- Vol. 38 (6) , 550-558
Socioeconomic and psychological impact of treatment for unilateral intraocular retinoblastoma